The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience. Abstract #1294

Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Aim(s): evaluation efficacy and toxicity
Materials and methods: All pts received long acting somatostatin analogs.The mean age was 55 years, 4 male, 15 female. The most of pts had pancreatic neuroendocrine tumor – 16(84%)pts, kidney NET–1 pt,primary multiple synchronous panceatic+kidney had 2 patients.There was index proliferation Ki67% determination: Ki67 less 3% -1 pt, Ki67%= 3-20% had 15pts; ki67% more than 20% had 2pts. There were 3 pts with G1 NETs, 16 patients with G2 NETs.Cytoreductive surgery was performed in 9 -47,3%pts. 6/19 pts had 0-1-2 prior lines of CT and 13/19 patients were heavily pretreated with more than 3 lines of CT. Previous treatment included interferon α, octreotide LAR, XelOx, EP and of temozolomide, paclitaxel and fluoropyrimidines, everolimus. Sunitinib as a first line treatment was in 3 patients, after everolimus therapy was in 2 cases.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#1702 Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).
Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.